217 related articles for article (PubMed ID: 38168866)
1. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
2. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
4. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
[TBL] [Abstract][Full Text] [Related]
5. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
7. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
9. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
10. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
11. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
13. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
[TBL] [Abstract][Full Text] [Related]
15. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
16. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
18. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy.
Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
Arch Ital Urol Androl; 2022 Dec; 94(4):521-524. PubMed ID: 36576460
[TBL] [Abstract][Full Text] [Related]
20. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
